Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bradley Campbell, President and Chief Executive Officer, will deliver a presentation in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT.
The presentation will be accessible through a live audio webcast via the investors section of the Amicus Therapeutics corporate website. The company, dedicated to discovering, developing, and delivering novel medicines for rare diseases, maintains a commitment to advancing its pipeline of first- or best-in-class medicines.
Amicus Therapeutics (Nasdaq: FOLD), una società biotecnologica globale focalizzata sulle malattie rare, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Bradley Campbell, Presidente e Amministratore Delegato, terrà una presentazione a San Francisco lunedì 13 gennaio 2025, alle 15:00 PT.
La presentazione sarà accessibile tramite un webcast audio dal vivo nella sezione investitori del sito web aziendale di Amicus Therapeutics. L'azienda, dedicata alla scoperta, allo sviluppo e alla fornitura di medicine innovative per malattie rare, mantiene un impegno costante nell'avanzamento della sua pipeline di medicinali di prima o migliore classe.
Amicus Therapeutics (Nasdaq: FOLD), una empresa biotecnológica global centrada en enfermedades raras, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. Bradley Campbell, Presidente y Director Ejecutivo, realizará una presentación en San Francisco el lunes 13 de enero de 2025, a las 3:00 p.m. PT.
La presentación será accesible a través de una transmisión de audio en vivo en la sección de inversores del sitio web corporativo de Amicus Therapeutics. La empresa, que se dedica a descubrir, desarrollar y ofrecer medicamentos novedosos para enfermedades raras, mantiene un compromiso con el avance de su cartera de medicamentos de primera o mejor clase.
아미커스 테라퓨틱스 (Nasdaq: FOLD), 희귀 질환에 집중하는 글로벌 생명공학 회사가 제43회 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 브래들리 캠벨, 사장 겸 CEO가 2025년 1월 13일 월요일, 오후 3시 PT에 샌프란시스코에서 발표를 진행할 예정입니다.
이 발표는 아미커스 테라퓨틱스 기업 웹사이트의 투자자 섹션을 통해 실시간 오디오 웨비나로 접근할 수 있습니다. 이 회사는 희귀 질환을 위한 혁신적인 의약품의 발견, 개발 및 제공에 전념하며, 1류 또는 최우수 의약품 파이프라인의 발전에 대한 헌신을 유지하고 있습니다.
Amicus Therapeutics (Nasdaq: FOLD), une entreprise biopharmaceutique mondiale axée sur les maladies rares, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Bradley Campbell, Président-directeur général, fera une présentation à San Francisco le lundi 13 janvier 2025 à 15h00 PT.
La présentation sera accessible par le biais d'un webcast audio en direct dans la section investisseurs du site web de l'entreprise Amicus Therapeutics. L'entreprise, dédiée à la découverte, au développement et à la fourniture de médicaments innovants pour les maladies rares, reste engagée à faire progresser son portefeuille de médicaments de premier choix ou de meilleure qualité.
Amicus Therapeutics (Nasdaq: FOLD), ein globales Biotechnologieunternehmen, das sich auf seltene Krankheiten konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Bradley Campbell, Präsident und Geschäftsführer, wird am Montag, den 13. Januar 2025, um 15:00 Uhr PT in San Francisco eine Präsentation halten.
Die Präsentation wird über einen Live-Audio-Webcast im Bereich für Investoren der Unternehmenswebsite von Amicus Therapeutics zugänglich sein. Das Unternehmen, das sich der Entdeckung, Entwicklung und Bereitstellung neuartiger Medikamente für seltene Krankheiten widmet, bleibt dem Fortschritt seiner Pipeline von erstklassigen oder besten Medikamenten verpflichtet.
- None.
- None.
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT.
A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When is Amicus Therapeutics (FOLD) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors access the FOLD presentation at the J.P. Morgan Healthcare Conference?
What is the main focus of Amicus Therapeutics (FOLD)?
Who will represent FOLD at the 2025 J.P. Morgan Healthcare Conference?
